Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle
By LizaAVILA
Featured Article
Academic Journal
Main Category: Stem Cell Research
Also Included In: Cardiovascular / Cardiology
Article Date: 14 Feb 2012 - 2:00 PST
email to a friend printer friendly opinions
Current Article Ratings:
Patient / Public:
5 (1 votes)
Healthcare Prof:
Details of a small clinical trial published in The Lancet on Tuesday reveal how scientists helped patients with hearts damaged by heart attack to re-grow healthy heart muscle and reduce scar tissue with an infusion of stem cells taken from the patients' own hearts.
Leading international cardiologist and heart researcher Dr Eduardo Marbán, who is director of the Cedars-Sinai Heart Institute in Los Angeles and Mark S. Siegel Family Professor, is senior author of the study. He told the press what they saw in the trial:
"... challenges the conventional wisdom that, once established, scar is permanent and that, once lost, healthy heart muscle cannot be restored."
In 2009, Marbán and his team had already shown it is possible, following a heart attack, to grow specialized stem cells from the patient's own heart tissue (called cardiosphere-derived cells or CDCs), inject them back into the patient's damaged heart, and see they reduce scars, increase muscle and boost cardiac function.
The purpose of the clinical trial (called CADUCEUS, short for CArdiosphere-Derived aUtologous stem CElls to Reverse ventricUlar dySfunction) was to assess the safety of such a procedure to repair damage in the left ventricle after a heart attack.
For the trial, which took place at two centres, the Cedars-Sinai Heart Institute and Johns Hopkins Hospital in Baltimore, the researchers enrolled 25 patients of average age 53, who had experienced heart attacks two to four weeks earlier.
Each patient underwent extensive imaging scans to locate and assess the severity of the scars caused by their heart attacks.
The heart attacks had left the patients with damage to their left ventricle, such that their "left ventricular ejection fraction" was between 20 and 45%, and on average, the scar tissue occupied 24% of left ventricular mass.
The patients were randomly allocated in a two to one ratio to either receive stem cell therapy or standard care (the controls). Standard care comprised conventional medical care for heart attack survivors, including prescription medicine and advice on exercise and diet.
The 17 patients assigned to receive stem cell therapy underwent a minimally invasive biopsy under local anesthetic. During this procedure, doctors inserted a catheter through a vein in the patient's neck and removed small pieces of heart tissue, about half the size of a raisin.
Back in Marbán's specialized lab at Cedars-Sinai, the researchers used the pieces of heart muscle to grow autologous CDCs.
When enough CDCs had grown (between 12 and 25 million of them), they re-introduced them into the patients' coronary arteries. This was also done with a minimally invasive catheter procedure. By this time it was 1.5 to 3 months after their heart attacks.
The results showed that:
No complications were reported within 24 hours of receiving infusions.
By month 6, no patients had died, developed cardiac tumors or a major adverse cardiac event, although four patients in the CDC group had serious adverse events compared with one control.
Imaging scans at month 6 showed that compared to controls, the CDC group had significant reductions in scar mass, increases in viable heart mass, regional contractility, and regional systolic wall thickening.
At month 12 the CDC group showed average of 50% reduction in their heart attack scars (from 24% to 12%) while the controls did not show any reduction.
However, changes in end-diastolic volume, end-systolic volume, and left ventricular ejection fraction did not differ between groups at month 6. Marbán said:
"While the primary goal of our study was to verify safety, we also looked for evidence that the treatment might dissolve scar and regrow lost heart muscle."
"This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it. The effects are substantial, and surprisingly larger in humans than they were in animal tests," he added.
Dr Shlomo Melmed, dean of the Cedars-Sinai medical faculty and the Helene A and Philip E. Hixon Chair in Investigative Medicine, describes the study as a "paradigm shift" in heart attack care.
"In the past, all we could do was to try to minimize heart damage by promptly opening up an occluded artery. Now, this study shows there is a regenerative therapy that may actually reverse the damage caused by a heart attack," said Melmed.
The trial was part of a phase I investigative study approved by the Food and Drug Administration (FDA) in the US. Funding came from the US National Heart, Lung, and Blood Institute and Cedars-Sinai Board of Governors Heart Stem Cell Center.
The method for growing CDCs in the lab was developed by Marbán when he was on the faculty of Johns Hopkins University, who have now filed for an intellectual property patent and licensed it to a company in which Marbán has a financial interest. However, that company did not provide funds for the study.
Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
Visit our stem cell research section for the latest news on this subject. "Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial"; Raj R Makkar, Rachel R Smith, Ke Cheng, Konstantinos Malliaras, Louise EJ Thomson, Daniel Berman, Lawrence SC Czer, Linda Marbán, Adam Mendizabal, Peter V Johnston, Stuart D Russell, Karl H Schuleri, Albert C Lardo, Gary Gerstenblith, Eduardo Marbán; The Lancet, published early online 14 February 2012; DOI: 10.1016/S0140-6736(12)60195-0; Link to Abstract
Additional source: Cedars-Sinai Medical Center Please use one of the following formats to cite this article in your essay, paper or report:
MLA
Catharine Paddock PhD. "Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle." Medical News Today. MediLexicon, Intl., 14 Feb. 2012. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/articles/241592.php>
APA
Please note: If no author information is provided, the source is cited instead.
Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
See original here:
Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle
- Developing the Cell-Based Therapies of the Future - University of Miami - November 15th, 2024
- Advancing heart stem cell therapy - UHN Foundation - November 15th, 2024
- Heart defects affect 40,000 US babies every year but cutting edge AI and stem cell tech will save lives and even cure them in the womb - New York... - November 15th, 2024
- Science Is Finding Ways to Regenerate Your Heart - The Wall Street Journal - November 6th, 2024
- AIIMS Bathinda Makes Breakthrough in Stem Cell Therapy Research for Heart Ailments - Elets - October 21st, 2024
- USC launches collaboration with StemCardia to advance heart regeneration therapies - University of Southern California - October 13th, 2024
- The heart is a resident tissue for hematopoietic stem and progenitor cells in zebrafish - Nature.com - September 3rd, 2024
- Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer - July 16th, 2024
- Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome... - July 16th, 2024
- AstraZeneca Closes Acquisition of Amolyt Pharma - July 16th, 2024
- Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) - July 16th, 2024
- Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - July 16th, 2024
- ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder - July 16th, 2024
- MediWound Announces $25 Million Strategic Private Placement Financing - July 16th, 2024
- Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair - July 16th, 2024
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - July 16th, 2024
- Kraig Biocraft Laboratories Completes Phase One of its Spider Silk Production Facility Expansion - July 16th, 2024
- Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with... - July 16th, 2024
- Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic... - July 16th, 2024
- Rectify Pharmaceuticals Appoints Bharat Reddy as Chief Business Officer - July 16th, 2024
- Spectral AI Continues Support of Naked Short Selling Inquiry - July 16th, 2024
- Milestone Pharmaceuticals Refreshes Board of Directors - July 16th, 2024
- New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure - July 16th, 2024
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 21st, 2023
- Cardiac stem cells: Current knowledge and future prospects - April 13th, 2023
- Stem cell therapies in cardiac diseases: Current status and future ... - April 13th, 2023
- Stem Cell and Regenerative Biology | Johns Hopkins Heart and Vascular ... - April 13th, 2023
- Center for Regenerative Biotherapeutics - Cardiac Regeneration - April 13th, 2023
- MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 25th, 2023
- CAREDX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 1st, 2023
- A Possible Connection between Mild Allergic Airway Responses and Cardiovascular Risk Featured in Toxicological Sciences - Newswise - February 4th, 2023
- Baby's life saved by surgeon who carried out world's first surgery ... - December 25th, 2022
- An organoid model of colorectal circulating tumor cells with stem cell ... - December 25th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - December 1st, 2022
- Stem-cell niche - Wikipedia - December 1st, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Scientists Spliced Human Brain Tissue Into The Brains of Baby Rats - ScienceAlert - October 13th, 2022
- Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution | Communications Biology - Nature.com - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine -... - October 13th, 2022
- Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite - October 5th, 2022
- 'Love hormone' oxytocin could help reverse damage from heart attacks via cell regeneration - Study Finds - October 5th, 2022
- Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD - Pharmaceutical Executive - September 27th, 2022
- Adult Stem Cells // Center for Stem Cells and Regenerative Medicine ... - September 19th, 2022
- CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease - Cardiovascular Diabetology - Cardiovascular... - September 19th, 2022
- Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and... - September 19th, 2022
- Neural crest - Wikipedia - September 3rd, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 3rd, 2022
- Discover the Mental and Physical Health Benefits of Fasting - Intelligent Living - September 3rd, 2022
- Heart Association fellowship to support research - Binghamton - August 26th, 2022
- Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration | Communications Biology -... - August 26th, 2022
- High intensity interval training protects the heart against acute myocardial infarction through SDF-1a, CXCR4 receptors and c-kit levels - Newswise - August 26th, 2022
- Yale University: Uncovering New Approaches to a Common Inherited Heart Disorder | India Education - India Education Diary - August 10th, 2022
- Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery | International Journal of Obesity -... - August 10th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 10th, 2022
- Protocol for a Nested, Retrospective Study of the Australian Placental Transfusion Study Cohort - Cureus - August 10th, 2022
- Autologous Cell Therapy Market Size to Grow by USD 4.11 billion, Bayer AG and Brainstorm Cell Therapeutics Inc. Among Key Vendors - Technavio - PR... - August 2nd, 2022
- UTSW researcher part of team awarded $36 million heart research grant - The Dallas Morning News - August 2nd, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 2nd, 2022
- Hyperglycaemia-Induced Impairment of the Autorhythmicity and Gap Junction Activity of Mouse Embryonic Stem Cell-Derived Cardiomyocyte-Like Cells -... - July 25th, 2022
- NASA's Solution to Stem Cell Production is Out of this World - BioSpace - July 25th, 2022
- Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor | Signal Transduction and Targeted Therapy - Nature.com - July 25th, 2022
- 'My Teen Sweetheart And I Drifted Apart. 30 Years Later I Made a Shocking Discovery' - Newsweek - July 25th, 2022
- EU: New Blood? Proposed Revisions to the EUs Blood, Tissues and Cells Rules - GlobalComplianceNews - July 25th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 25th, 2022
- Cell Separation Technologies Market Expands with Rise in Prevalence of Chronic Diseases, States TMR Study - GlobeNewswire - July 25th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 25th, 2022
- Stem Cells Used to Repair Heart Defects in Children - NBC 5 Dallas-Fort Worth - July 16th, 2022
- Pneumonia and Heart Disease: What You Should Know - Healthline - July 16th, 2022
- Promising solution to fatal genetic-disorder complications discovered by University professor and Ph.D. candidate - Nevada Today - July 16th, 2022
- Current and advanced therapies for chronic wound infection - The Pharmaceutical Journal - July 16th, 2022
- Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz - July 16th, 2022
- Mesenchymal stem cells: from roots to boost - PMC - July 8th, 2022
- New study allows researchers to more efficiently form human heart cells from stem cells - University of Wisconsin-Madison - July 8th, 2022
- Dr Victor Chang saved hundreds of lives. 31 years ago today, he was murdered. - Mamamia - July 8th, 2022
- Exosome Therapeutics Market Research Report Size, Share, New Trends and Opportunity, Competitive Analysis and Future Forecast Designer Women -... - July 8th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 8th, 2022
- Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and... - July 8th, 2022
- What New Advances are there in 3D Bioprinting Tissues? - AZoM - June 30th, 2022